Article Text

Download PDFPDF
Family History of Cancer Rather Than p53 Status Predicts Efficacy of Pegylated Liposomal Doxorubicin and Oxaliplatin in Relapsed Ovarian Cancer
  1. Maria Ornella Nicoletto, MD*,
  2. Roberta Bertorelle, PhD*,
  3. Lucia Borgato, MD*,
  4. Gian Luca De Salvo, MD*,
  5. Grazia Artioli, MD*,
  6. Giuseppe Lombardi, MD*,
  7. Fable Zustovich, MD*,
  8. Raffaella Marcato, PhD*,
  9. Anna Parenti, MD,
  10. Marco Montagna, PhD* and
  11. Martin E. Donach, MD*
  1. * Istituto Oncologico Veneto-IRCCS; and
  2. Department of Pathology, University of Padova, Padova, Italy.
  1. Address correspondence and reprint requests to Maria Ornella Nicoletto, Oncologia Medica 1, Istituto Oncologico Veneto IRCCS, via Gattamelata 64, 35128 Padova, Italy. E-mail: mariaorn{at}


Background: The aim of the study was to assess the efficacy of pegylated liposomal doxorubicin (PLD) and oxaliplatin in patients affected by relapsed epithelial ovarian cancer with a family history of BRCA and p53 mutations.

Methods: Seventy-two women received a median of 7.5 courses of PLD at 30 to 35 mg/m2 plus oxaliplatin at 70 mg/m2, and associations between BRCA1/2 and TP53 status and overall survival (OS) were determined. Thirty-eight had a short platinum-free interval (PFI; <12 months), and 34 had a long PFI (≥12 months).

Results: Nine patients had BRCA1 mutations, and 1 had a BRCA2 mutation. Platinum sensitivity was associated with OS (P = 0.0001). At a median follow-up of 9.3 months, objective response rate, median time to progression, and OS were 47.3%, 5.8 months, and 12.9 months, respectively, in short PFI compared with the 76.5%, 11.5 months, and 47.7 months in long PFI. p53 status did not correlate to these parameters. The median time to progression was 11.5 months for high-risk patients versus 6.5 months for patients with sporadic cancer (P = 0.0188), and the median OS from the start of treatment was 48.7 and 16.2 months (P = 0.0032), respectively. Toxicity was mostly grade 1 or 2.

Conclusions: High response rates in the long-PFI patients indicate that this treatment is beneficial and well tolerated. Platinum sensitivity and positive family history and/or a BRCA1/BRCA2 mutation are a useful predictor of response.

  • Ovarian cancer
  • BRCA
  • p53
  • PLD
  • Oxaliplatin

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.